Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel
|ClinicalTrials.gov Identifier: NCT00159003|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : August 10, 2017
There are naturally occuring variations in the genetic makeup of all of us. Some of these variations may contribute to a change in susceptibility toward different diseases or change the prognosis.
We are studying these genetic variations in patients with leukemia. The genes we are studying are those which influence detoxification of drugs and toxins.
|Condition or disease|
|Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia|
We have prepared DNA on patients with leukemia (AML, CML and CLL) and we are studying the influence of polymorphisms in drug metabolism and disposition genes on predisposition and prognosis of these types of leukemia. The genes we are studying include: MDR1, CYP3A4, NQO1, NAT1/2, GST, hOCT. We plan to study other genes that may be contributory.
Study includes comparing the frequency of polymorphisms in these genes with the frequency in the general population and the study of DNA biding proteins which bind at the sites of these polymorphisms.
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Official Title:||Molecular Analysis of Genetic Elements Which May Influence Predisposition and Prognosis of Hematological Malignancies in Different Ethnic Groups in Israel|
|Actual Study Start Date :||January 1, 1998|
|Primary Completion Date :||July 1, 2017|
|Study Completion Date :||July 1, 2017|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159003
|Hadassah Medical Organization|
|Jerusalem, Israel, IL91120|
|Principal Investigator:||Deborah G Rund, MD||Hadassah Medical Organization|